Patheon has signed a strategic agreement with Grünenthal, a research-based pharmaceutical group based in Germany, to serve as its preferred development partner for its products using Grünenthal’s abuse deterrent formulation technology INTAC. Patheon will assist with the development of advanced INTAC-based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. Grünenthal will install specialized equipment in Patheon’s...